Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis

Weidinger, 2018, Atopic dermatitis, Nat Rev Dis Primers, 4, 1, 10.1038/s41572-018-0001-z Bylund, 2020, Prevalence and incidence of atopic dermatitis: a systematic review, Acta Derm Venereol, 100, 10.2340/00015555-3510 Silverberg, 2019, Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults, Br J Dermatol, 181, 554, 10.1111/bjd.17683 de Bruin-Weller, 2020, The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada, J Eur Acad Dermatol Venereol, 34, 1026, 10.1111/jdv.16003 Simpson, 2018, Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis, JAMA Dermatol, 154, 903, 10.1001/jamadermatol.2018.1572 Girolomoni, 2021, The economic and psychosocial comorbidity burden among adults with moderate-to-severe atopic dermatitis in Europe: analysis of a cross-sectional survey, Dermatol Ther (Heidelb), 11, 117, 10.1007/s13555-020-00459-8 Wei, 2018, Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis, J Dermatol, 45, 150, 10.1111/1346-8138.14116 Boguniewicz, 2018, Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape, Ann Allergy Asthma Immunol, 120, 10, 10.1016/j.anai.2017.10.039 Blauvelt, 2017, Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial, Lancet, 389, 2287, 10.1016/S0140-6736(17)31191-1 Silverberg, 2021, What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study, Br J Dermatol, 184, 888, 10.1111/bjd.19457 Simpson, 2020, Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial, Lancet, 396, 255, 10.1016/S0140-6736(20)30732-7 Silverberg, 2020, Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial, JAMA Dermatol, 156, 863, 10.1001/jamadermatol.2020.1406 Bieber, 2021, Abrocitinib versus placebo or dupilumab for atopic dermatitis, N Engl J Med, 384, 1101, 10.1056/NEJMoa2019380 Hanifin, 2001, The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group, Exp Dermatol, 10, 11, 10.1034/j.1600-0625.2001.100102.x Finlay, 1994, Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use, Clin Exp Dermatol, 19, 210, 10.1111/j.1365-2230.1994.tb01167.x Basra, 2008, The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results, Br J Dermatol, 159, 997 Yosipovitch, 2019, Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis, Br J Dermatol, 181, 761, 10.1111/bjd.17744 von Kobyletzki, 2017, What factors are important to patients when assessing treatment response: an international cross-sectional survey, Acta Derm Venereol, 97, 86, 10.2340/00015555-2480 Okubo, 2020, Patient and physician preferences for atopic dermatitis injection treatments in Japan, J Dermatolog Treat, 31, 821, 10.1080/09546634.2019.1623860 Boeri, 2020, Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment, J Dermatolog Treat, 1 Egeberg, 2019, Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis, J Am Acad Dermatol, 81, 943, 10.1016/j.jaad.2019.06.018 Sunzini, 2020, JAK inhibitors and infections risk: focus on herpes zoster, Ther Adv Musculoskelet Dis, 12, 10.1177/1759720X20936059 Bieber, 2022, Atopic dermatitis: an expanding therapeutic pipeline for a complex disease, Nat Rev Drug Discov, 21, 21, 10.1038/s41573-021-00266-6 Simpson, 2021, Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program, Am J Clin Dermatol, 22, 693, 10.1007/s40257-021-00618-3 Wojciechowski, 2022, Population pharmacokinetics of abrocitinib in healthy individuals and patients with psoriasis or atopic dermatitis, Clin Pharmacokinet, 61, 709, 10.1007/s40262-021-01104-z